• Ocular Therapeutix (OCUL) PDUFA of DEXTENZA for post-surgical ocular pain

       (0 reviews)

    Biotech Forecast
    Clinical and Regulatory
    Event Type: PDUFA
    Timing: 07/24/2016
    Designation(s): None

    This event is set for a specific date and makes planning easier. However, specific dates may change.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Opthamology
    Indication: post-surgical ocular pain
    Lead Indication?: No
    Treatment Name: DEXTENZA

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Ocular Therapeutix
    Stock Symbol: OCUL
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://investors.ocutx.com/phoenix.zhtml?c=253650&p=irol-newsArticle&ID=2147465
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement


    PDUFA target action date of July 24, 2016 for the NDA for DEXTENZA™ for the treatment of post-surgical ocular pain


      Report Event

    User Feedback

    There are no reviews to display.